Bristol-Myers Squibb Company
(BMY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 48,194,000 | 48,300,000 | 45,006,000 | 46,159,000 | 46,385,000 |
| Cost of Goods | 13,936,000 | 13,968,000 | 10,693,000 | 10,137,000 | 9,940,000 |
| Gross Profit | 34,258,000 | 34,332,000 | 34,313,000 | 36,022,000 | 36,445,000 |
| Operating Expenses | 24,930,000 | 42,711,000 | 25,873,000 | 28,309,000 | 28,347,000 |
| Operating Income | 9,328,000 | -8,379,000 | 8,440,000 | 7,713,000 | 8,098,000 |
| Pre-tax Income | 9,328,000 | -8,379,000 | 8,440,000 | 7,713,000 | 8,098,000 |
| Income Tax | 2,272,000 | 554,000 | 400,000 | 1,368,000 | 1,084,000 |
| Net Income Continuous | 7,056,000 | -8,933,000 | 8,040,000 | 6,345,000 | 7,014,000 |
| Minority Interests | 2,000 | 15,000 | 15,000 | 18,000 | 20,000 |
| Net Income | $7,054,000 | $-8,948,000 | $8,025,000 | $6,327,000 | $6,994,000 |
| EPS Basic Total Ops | 3.47 | -4.41 | 3.88 | 2.97 | 3.15 |
| EPS Basic Continuous Ops | 3.47 | -4.41 | 3.89 | 2.98 | 3.16 |
| EPS Diluted Total Ops | 3.46 | -4.41 | 3.86 | 2.95 | 3.12 |
| EPS Diluted Continuous Ops | 3.46 | -4.41 | 3.87 | 2.96 | 3.12 |
| EPS Diluted Before Non-Recurring Items | 6.15 | 1.15 | 7.51 | 7.70 | 7.51 |
| EBITDA(a) | $13,339,000 | $1,221,000 | $18,200,000 | $17,989,000 | $18,784,000 |